OncoMatch/Clinical Trials/NCT07856212

Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia

Official title: Impact of Maintenance Therapy With Fluoropyrimidines, Immunotherapy or Targeted Therapies in Metastatic Gastric Cancer: A Retrospective Multicenter Study in High-Complexity Institutions in Latin America

Is NCT07856212 recruiting? Yes, currently enrolling (Oct 2026). Studying multiple treatments including Fluoropyrimidine Maintenance Therapy and Immune Checkpoint Inhibitor Maintenance for stomach neoplasms.

Treatment: Fluoropyrimidine Maintenance Therapy · Immune Checkpoint Inhibitor Maintenance · Targeted Therapy Maintenance — Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued. Maintenance therapy, in which patients whose disease is at least stable after induction chemotherapy continue on a less toxic regimen, is increasingly used, most often with fluoropyrimidines (capecitabine, 5-fluorouracil or S-1) and, in selected molecular subgroups, with immunotherapy or targeted therapy. Evidence on the outcomes of these strategies in Latin American patients is scarce. This multicenter retrospective study will review the medical records of adults with metastatic gastric cancer treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia, who received maintenance therapy after achieving at least stable disease with induction chemotherapy. The study will describe the demographic, clinical, pathological and molecular characteristics of these patients and estimate overall survival, progression-free survival, treatment response, toxicity and mortality. The investigators will not assign or modify any treatment.